Briefing
Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA)
The Oncologist abstract 7 reports the same NCT03575611 ctDNA analysis as AACR CT132, with baseline MRD+ in 56% (STFS HR 2.9, 27 vs 54 months) and 3-month MRD+ STFS HR 4.3; a few clinical tallies differ slightly from CT132 and are not pooled.
- n: 121 patients (NCT03575611)
- Assay: Individualized ctDNA panels (Myriad Genetics) from tumor whole-genome sequencing